Figure 4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Internal validation of the b.TRPC model and comparison with ctDNA%. A and B, ROC curves comparing the predictive performance of b.TRPC and ctDNA% for 0.5-, 1-, and 2-year CRPC-free survival. C and D, Calibration plots showing the agreement between predicted and observed survival probabilities for b.TRPC and ctDNA%. E, C-index values demonstrating the superior prognostic accuracy of b.TRPC compared with ctDNA%. F–H, DCA illustrating the net clinical benefit of b.TRPC across different time points. FPR, false positive rate; TPR, true positive rate.